FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
|Articles|November 26, 2014
CTCL Treatments - The Old and New - Part 1
Alain H. Rook, MD, Professor of Dermatology, University of Pennsylvania, Perelman School of Medicine provides part one of a three part overview of treatments for cutaneous lymphoma.
Advertisement
Alain H. Rook, MD, Professor of Dermatology, University of Pennsylvania, Perelman School of Medicine provides part one of a three part overview of treatments for cutaneous lymphoma.
Advertisement
Related to this article
Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175.
In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient end-stage hematology care.
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
2
IMS 2026: Beth Faiman Talks New Definition of Myeloma Cure and More
3
FDA Approves Maintenance Tucatinib for Advanced HER2+ Breast Cancer
4
Surveillance, Patient Resources, and Financial Support
5